Neurocrine Biosciences (NBIX) Stock

SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has started a Phase 3 study to assess how effective, safe, and tolerable osavampator (previously known as NBI-1065845) is as an additional treatment alongside antidepressants for major depressive disorder (MDD). In April 2024, they shared positive initial results from the Phase 2 SAVITRI™ study involving adults with MDD.

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced the release of a special supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) that focuses on classic congenital adrenal hyperplasia (CAH). The supplement, named "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," includes eight review articles that explore the various clinical, psychosocial, treatment-related, and everyday challenges faced by those living with classic CAH.

A recent narrative review highlights the difficulties of using glucocorticoids (GCs) as the only treatment for classic congenital adrenal hyperplasia (CAH) and explores new non-GC treatment options. These alternative methods could help manage excess ACTH and androgens while allowing for lower doses of GCs, which may reduce complications over a person's lifetime. The review was published in the Expert Review of Endocrinology & Metabolism.

CRENESSITY, a new treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now available in the U.S. Patients can get support from CAH-trained pharmacists at PANTHERx Rare, a specialty pharmacy, which operates 24/7. Neurocrine Access Support also offers free information and assistance to patients, caregivers, and healthcare providers.

CRENESSITY is a groundbreaking new treatment for classic congenital adrenal hyperplasia (CAH), marking the first significant advancement in 70 years. Recently approved by the FDA, it is designed to help manage androgens in both adults and children aged four and older with this rare genetic condition. This treatment works by directly lowering excess adrenocorticotropic hormone (ACTH) levels, which can help reduce the need for glucocorticoids.

On Friday, the U.S. Food and Drug Administration announced that it has approved a medication from Neurocrine Biosciences for a specific genetic disorder, according to information on their website.

Neurocrine Biosciences, Inc. saw its share price drop in August due to disappointing phase 2 results for NBI-568 in schizophrenia patients, which makes sense, but the extent of the decline is surprising. The company is valued like a slow-growing big pharmaceutical firm, even though it has strong growth potential. Ingrezza is still generating solid growth and cash flow, and crinecerfont is set to launch in early 2025.

At the 2024 Psych Congress, Neurocrine Biosciences, Inc. shared findings from over 300 patients with tardive dyskinesia who were treated with INGREZZA® (valbenazine) capsules. The results indicated notable enhancements in various aspects of quality of life, including functional, social, emotional, and health-related measures from Phase 3 and 4 studies. Additionally, improvements were observed in patients' independence, emotional well-being, physical health, and adherence to antipsychotic medication in real-world settings.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) held its Q3 2024 Earnings Conference Call on August 30, 2024, at 8:00 AM ET. Key participants included CEO Kyle Gano, CFO Matt Abernethy, and other executives. Various analysts from firms like Goldman Sachs, Stifel, and J.P. Morgan also joined the call to discuss the company's third-quarter results.